Sun Pharma's ILUMYA gets US nod for psoriatic arthritis: What patients need to know
The drug, already used to treat plaque psoriasis, has received US FDA approval for adults with active psoriatic arthritis. Here's how the treatment works and what patients should know about its benefits and risks.
Adults living with psoriatic arthritis in the US have a new treatment option following the approval of ILUMYA (tildrakizumab-asmn), a biologic medicine developed by Sun Pharmaceutical Industries. The US Food and Drug Administration (FDA) has cleared the drug for adults with active psoriatic arthritis, expanding its existing use in moderate-to-severe plaque psoriasis.
Psoriatic arthritis is a long-term inflammatory disease that affects the joints and can also cause swelling and pain where tendons and ligaments attach to bones. Symptoms may include joint stiffness, swelling, tenderness and difficulty moving. Without adequate control, inflammation can cause lasting joint damage.
The condition affects an estimated 2.4 million people in the US, according to Sun Pharma. It can develop at any age and does not necessarily correspond to the severity of a person's skin psoriasis.
What is ILUMYA and how does it work?
ILUMYA belongs to a class of medicines known as interleukin-23 (IL-23) inhibitors. These drugs target a protein involved in the immune system's inflammatory response.
Also read: Lilly’s retatrutide outperforms Ozempic on weight loss in diabetes trial; safety concerns remain
In people with psoriatic disease, this inflammatory pathway can contribute to symptoms affecting both the skin and joints. By blocking the p19 subunit of IL-23, tildrakizumab is designed to reduce inflammatory activity.
The medicine was approved in the US in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic treatment or phototherapy. The latest approval extends its use to adults with active psoriatic arthritis.
Unlike medicines that patients administer themselves at home, ILUMYA is given by a healthcare professional. This may suit patients who prefer supervised treatment, although the choice of medicine depends on an individual's condition, medical history and treatment needs.
The approval does not mean the drug is appropriate for everyone with psoriatic arthritis. Treatment decisions depend on factors such as joint symptoms, disease activity, other health conditions and previous responses to medication.
What did the clinical trials find?
The approval was supported by two Phase 3 clinical trials, INSPIRE-1 and INSPIRE-2, which evaluated tildrakizumab 100 mg in adults with active psoriatic arthritis.
The studies were designed to assess the medicine's effectiveness and safety over 52 weeks. According to the company, the approval was supported by assessments following two doses at week 24.
Also read: The hidden toll of India's air pollution: How PM2.5 affects long-term health
The company also reported that the studies did not identify any new safety signals. However, this does not mean the medicine is free of risks, and the findings should be considered alongside the full clinical trial data and prescribing information.
For patients, an important question is how much a treatment can improve symptoms, physical function and quality of life, and whether those benefits outweigh potential side effects. Doctors must assess these factors when recommending a biologic medicine.
Who should be cautious about the treatment?
ILUMYA can increase the risk of infections. Patients should be assessed for tuberculosis (TB) before starting treatment. Those with active TB should not receive the medicine, while patients with latent TB may need treatment before beginning therapy.
People with an active infection should generally wait until it has resolved or been adequately treated before starting ILUMYA. Patients who develop a serious infection during treatment may need close monitoring and temporary discontinuation, depending on their doctor's assessment.
The medicine is also contraindicated in people who have previously experienced a serious allergic reaction to tildrakizumab or any of its ingredients. Live vaccines should be avoided during treatment.
The most common adverse reactions reported in the psoriatic arthritis studies were upper respiratory tract infections and COVID-19.
Patients should discuss their infection history, existing medical conditions and vaccination status with their healthcare provider before treatment.
Why does the approval matter?
Psoriatic arthritis can be challenging to manage because it affects people differently. Some patients experience predominantly joint symptoms, while others have both joint inflammation and skin psoriasis. Treatment may involve conventional disease-modifying medicines, biologic therapies or other targeted drugs.
The availability of another approved treatment gives doctors an additional option to consider. However, the most suitable medicine will vary from patient to patient, and the latest approval does not establish that ILUMYA is more effective than existing alternatives.
The approval announced by Sun Pharma applies to the US. Patients in India should not assume that the same indication is automatically approved or available locally.
For people experiencing persistent joint pain, swelling or morning stiffness, particularly alongside psoriasis, medical evaluation is important. Early diagnosis and appropriate treatment can help control inflammation and reduce the risk of long-term joint damage.
